HRP960576B1 - Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl-2-quinolinone derivatives - Google Patents

Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl-2-quinolinone derivatives

Info

Publication number
HRP960576B1
HRP960576B1 HR960576A HRP960576A HRP960576B1 HR P960576 B1 HRP960576 B1 HR P960576B1 HR 960576 A HR960576 A HR 960576A HR P960576 A HRP960576 A HR P960576A HR P960576 B1 HRP960576 B1 HR P960576B1
Authority
HR
Croatia
Prior art keywords
imidazol
methyl
protein transferase
farnesyl protein
quinolinone derivatives
Prior art date
Application number
HR960576A
Other languages
English (en)
Inventor
Marc Gaston Venet
Patrick Rene Angibaud
Philippe Muller
Gerard Charles Sanz
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP960576A2 publication Critical patent/HRP960576A2/hr
Publication of HRP960576B1 publication Critical patent/HRP960576B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
HR960576A 1995-12-08 1996-12-05 Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl-2-quinolinone derivatives HRP960576B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95203427 1995-12-08

Publications (2)

Publication Number Publication Date
HRP960576A2 HRP960576A2 (en) 1998-02-28
HRP960576B1 true HRP960576B1 (en) 2002-04-30

Family

ID=8220926

Family Applications (1)

Application Number Title Priority Date Filing Date
HR960576A HRP960576B1 (en) 1995-12-08 1996-12-05 Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl-2-quinolinone derivatives

Country Status (36)

Country Link
US (3) US6037350A (fr)
EP (2) EP1162201B1 (fr)
JP (1) JP3257559B2 (fr)
KR (1) KR100272676B1 (fr)
CN (1) CN1101392C (fr)
AP (1) AP1108A (fr)
AR (1) AR004992A1 (fr)
AT (2) ATE321757T1 (fr)
AU (1) AU711142B2 (fr)
BG (1) BG62615B1 (fr)
BR (1) BR9610745A (fr)
CA (1) CA2231105C (fr)
CY (1) CY2289B1 (fr)
CZ (1) CZ293296B6 (fr)
DE (2) DE69620445T2 (fr)
DK (2) DK0865440T3 (fr)
EA (1) EA000710B1 (fr)
EE (1) EE03484B1 (fr)
ES (2) ES2175137T3 (fr)
HK (2) HK1012188A1 (fr)
HR (1) HRP960576B1 (fr)
HU (1) HU221227B1 (fr)
IL (1) IL123568A (fr)
MX (1) MX9802068A (fr)
MY (1) MY114444A (fr)
NO (1) NO314036B1 (fr)
NZ (1) NZ320244A (fr)
PL (1) PL184171B1 (fr)
PT (2) PT865440E (fr)
SI (2) SI1162201T1 (fr)
SK (1) SK283335B6 (fr)
TR (1) TR199800825T2 (fr)
TW (1) TW494101B (fr)
UA (1) UA57717C2 (fr)
WO (1) WO1997021701A1 (fr)
ZA (1) ZA9610254B (fr)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
NZ501401A (en) 1997-06-02 2002-03-28 Janssen Pharmaceutica Nv (Imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
US20030114503A1 (en) * 1997-06-16 2003-06-19 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
DE69915835T2 (de) * 1998-06-16 2005-03-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Imidazol-derivate
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
PT1094839E (pt) * 1998-07-06 2003-09-30 Janssen Pharmaceutica Nv Inibidores da proteina farnesil transferase com propriedades de radiossensibilizacao (in vivo)
EP1094815B1 (fr) * 1998-07-06 2003-11-12 Janssen Pharmaceutica N.V. Inhibiteurs de farnesyl proteine transferase pour le traitement des arthropathies
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
EA200100135A1 (ru) * 1998-08-27 2001-08-27 Пфайзер Продактс Инк. Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
ES2237125T3 (es) * 1998-08-27 2005-07-16 Pfizer Products Inc. Derivados de quinolin-2-ona utiles como agentes anticancerigenos.
US6284755B1 (en) 1998-12-08 2001-09-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2478500A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU765437B2 (en) 1998-12-23 2003-09-18 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
TR200201296T2 (tr) * 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (fr) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Dérivés de l'imidazole
FR2796943A1 (fr) * 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
RU2298417C2 (ru) * 1999-11-09 2007-05-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Продукт, включающий ингибитор трансдукции сигналов гетеротримерных протеинов g в комбинации с другим цитостатическим средством, для терапевтического применения при лечении рака
TR200400342T4 (tr) * 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil protein transferazı önlemek için kinolin türevleri.
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
SI1255537T1 (sl) * 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
EP1267848B1 (fr) * 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Regime posologique contenante inhibiteurs de la farnesyl proteine transferase pour le traitement du cancer
EP1267929A2 (fr) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Inhibiteur de farnesyl proteine transferase associe a un anticorps her2
AU2001240658A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with camptothecin compounds
WO2001064217A2 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteur de farnesyl proteine transferase et d'agents d'alkylation antitumoraux
CA2397253A1 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteurs de farnesyl proteine transferase et de derives antitumoraux d'anthracycline
AU2001246478A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
AU2001239275A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
CA2397694A1 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Combinaisons d'inhibiteur de farnesyl-proteine transferase
AU2001246477A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
CA2397475A1 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteurs de farnesyl proteine transferase et de vinca-alcaloides
WO2001064195A2 (fr) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Inhibiteur de farnesyl proteine transferase associe a des derives nucleosidiques anti-cancereux
JP2003525255A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
EP1322636A1 (fr) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Derives de la quinoleine et de la quinazoline 6- (phenyle substitue)methyle] inhibiteurs de la farnesyle transferase
ATE409189T1 (de) 2000-09-25 2008-10-15 Janssen Pharmaceutica Nv Farnesyl transferase-hemmende 6- heterocyclylmethyl-chinolin und chinazol-derivate
EP1322635B1 (fr) 2000-09-25 2006-03-22 Janssen Pharmaceutica N.V. Derives de quinoline et de quinazoline inhibant la farnesyl transferase comme inhibiteurs de farnesyl transferase
WO2002042296A1 (fr) * 2000-11-21 2002-05-30 Janssen Pharmaceutica N.V. Derives benzoheterocycliques inhibant la farnesyl transferase
DE60118953T2 (de) * 2000-11-28 2007-01-11 Janssen Pharmaceutica N.V. Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
WO2002050058A1 (fr) 2000-12-19 2002-06-27 Pfizer Products Inc. Formes cristallines de sels de 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinoleine-2-one, 2,3-dihydroxybutanedioate et procede de preparation
JP4351444B2 (ja) * 2000-12-27 2009-10-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する４−ヘテロシクリル−キノリンおよびキナゾリン誘導体
ES2260316T3 (es) * 2000-12-27 2006-11-01 Janssen Pharmaceutica N.V. Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa.
US6645966B2 (en) * 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
ES2318000T3 (es) * 2001-02-15 2009-05-01 Janssen Pharmaceutica Nv Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos.
NZ528620A (en) * 2001-03-12 2005-01-28 Janssen Pharmaceutica Nv Process for the preparation of imidazole compounds
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
EP1408971A4 (fr) 2001-06-21 2006-01-25 Ariad Pharma Inc Nouvelles quinoleines et leurs utilisations
WO2003000705A1 (fr) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Nouveaux quinolines et leurs utilisations
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US20030134846A1 (en) * 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
AU2002358677B2 (en) 2001-12-19 2008-02-07 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
ES2287466T3 (es) 2002-03-22 2007-12-16 Janssen Pharmaceutica N.V. Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa.
AU2003229688B2 (en) 2002-04-15 2009-07-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
EP1539234A4 (fr) * 2002-09-05 2006-02-15 Medimmune Inc Methodes de prevention ou de traitement de malignites cellulaires par administration d'antagonistes de cd2
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
AU2004259755A1 (en) * 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP2272566A3 (fr) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation d'anticorps
US7825131B2 (en) 2003-09-23 2010-11-02 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
EP1744751A4 (fr) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Traitement des synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
WO2005089504A2 (fr) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Procedes pour le traitement de synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20050288298A1 (en) * 2004-03-18 2005-12-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005105783A1 (fr) * 2004-05-03 2005-11-10 Janssen Pharmaceutica N.V. Procede de synthese diastereoselectif utilisant la 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline
CA2563807C (fr) * 2004-05-03 2012-11-20 Janssen Pharmaceutica N.V. Procede de synthese diastereoselective pour la preparation de composes imidazole
AU2005238221B2 (en) * 2004-05-03 2010-09-30 Janssen Pharmaceutica N.V. Diastereoselective addition of lithiated N-methylimidazole on sulfinimines
WO2006002422A2 (fr) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Composes utilises pour l'immunopotentialisation
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP2362218B1 (fr) 2004-11-05 2014-08-27 Janssen Pharmaceutica N.V. Methodes de controle de l'efficacite d'inhibiteurs de farnesyltransferase
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
CA2602035C (fr) 2005-03-18 2015-06-16 Medimmune, Inc. Rearrangement de l'infrastructure d'anticorps
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
WO2007002543A2 (fr) 2005-06-23 2007-01-04 Medimmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
EP1945182B1 (fr) * 2005-10-14 2010-07-28 Janssen Pharmaceutica N.V. Préparation de tipifarnib pour l'application intraveineuse
CA2634598A1 (fr) 2005-12-23 2007-07-05 Link Medicine Corporation Traitement de formes de synucleinopathie
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
SI2021335T1 (sl) * 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Heterocikliäśne spojine kot zaviralci c-fms kinaze
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
AU2007240443B2 (en) 2006-04-20 2012-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
DK2292663T3 (da) 2006-08-28 2013-11-04 Kyowa Hakko Kirin Co Ltd Antagonistiske human-let-specifikke, humane monoklonale antistoffer
WO2008039327A2 (fr) 2006-09-22 2008-04-03 Merck & Co., Inc. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
WO2008084261A1 (fr) 2007-01-10 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp)
BRPI0808523A2 (pt) 2007-03-01 2014-08-19 Novartis Vaccines & Diagnostic Inibidores de pim cinase e métodos de seu uso
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
JO2959B1 (en) 2007-05-14 2016-03-15 جانسين فارماسوتيكا ان. في Mono-hydrochloric salts for histone dacetylase inhibitor
CA2685967A1 (fr) 2007-05-21 2008-11-21 Novartis Ag Inhibiteurs de cfs-1r, compositions et methodes d'utilisation connexes
US8124774B2 (en) * 2007-05-23 2012-02-28 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
EP2170076B1 (fr) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
CN101848893B (zh) 2007-09-14 2012-06-06 奥梅-杨森制药有限公司 1,3-二取代的4-(芳基-x-苯基)-1h-吡啶-2-酮
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
MX2010004374A (es) 2007-10-31 2010-04-30 Medimmune Llc Armazones proteinicos.
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
US8940771B2 (en) 2007-12-20 2015-01-27 Novartis Ag Organic compounds
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2009151683A2 (fr) * 2008-03-12 2009-12-17 Link Medicine Corporation Inhibiteurs de quinolinone farnésyl transférase pour le traitement de synucléinopathies et d'autres indications
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010057006A1 (fr) * 2008-11-13 2010-05-20 Link Medicine Corporation Dérivés d'azaquinolinone et leurs applications
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110294794A1 (en) * 2008-11-13 2011-12-01 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
BRPI1012870B8 (pt) 2009-05-12 2021-05-25 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu uso como moduladores alostericos positivos de receptores de mglur2 e composição farmacêutica
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102480966B (zh) 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
NZ599343A (en) 2009-10-14 2014-05-30 Merck Sharp & Dohme Substituted piperidines that increase p53 activity and the uses thereof
CA2784807C (fr) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
AU2011227643A1 (en) 2010-03-16 2012-09-20 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
ES2705719T3 (es) 2010-07-28 2019-03-26 Janssen Diagnostics Llc Métodos de determinación de la respuesta de la leucemia mieloide aguda al tratamiento con inhibidores de la farnesiltransferasa
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
RU2624045C2 (ru) 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2608669B1 (fr) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CA2814998C (fr) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. Derives de 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
WO2012103165A2 (fr) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anticorps anti-kit et leurs utilisations
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
EP3358013B1 (fr) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (fr) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Procédé pour la préparation de dérivés d'ester hétérocyclique
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2014059028A1 (fr) 2012-10-09 2014-04-17 Igenica, Inc. Anticorps anti-c16orf54 et leurs méthodes d'utilisation
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
MX2015004784A (es) 2012-10-16 2015-08-14 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a fenilo de receptor nuclear de acido retinoico-gamma-t.
SI2909192T1 (sl) 2012-10-16 2017-08-31 Janssen Pharmaceutica Nv Metilensko vezani kinolinilni modulatorji za ROR-gama-t
EP2909194A1 (fr) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014063061A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
PT2925888T (pt) 2012-11-28 2017-12-13 Merck Sharp & Dohme Composições e métodos para tratamento do cancro
CA2895504A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituees en tant qu'inhibiteurs de hdm2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
ES2891755T3 (es) 2013-06-06 2022-01-31 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
KR20160054501A (ko) 2013-08-26 2016-05-16 맵백스 테라퓨틱스, 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
BR112016008258A2 (pt) 2013-10-15 2017-10-10 Janssen Pharmaceutica Nv moduladores de ror?t de quinolinila
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015058126A1 (fr) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Composés hétéroaromatiques utiles dans le traitement de maladies prolifératives
DK3076969T3 (da) 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
SI3431106T1 (sl) 2014-01-21 2021-03-31 Janssen Pharmaceutica Nv Kombinacije, ki vsebujejo pozitivne alosterične modulatorje metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CA3121083C (fr) 2014-06-04 2023-08-15 Biontech Research And Development, Inc. Anticorps monoclonaux humains contre le ganglioside gd2
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
SG11201704752WA (en) 2014-12-11 2017-07-28 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3265123B1 (fr) 2015-03-03 2022-10-26 Kymab Limited Anticorps, utilisations et procédés associés
WO2016160617A2 (fr) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
EP3307728A4 (fr) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
PT3640345T (pt) 2015-08-17 2021-12-29 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
US9815790B2 (en) 2015-08-27 2017-11-14 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CA3002954A1 (fr) 2015-11-02 2017-05-11 Novartis Ag Schema posologique pour un inhibiteur de la phosphatidylinositol 3-kinase
EP3383908A1 (fr) 2015-12-02 2018-10-10 Stsciences, Inc. Anticorps spécifiques au btla glycosylé (atténuateur de lymphocytes b et t)
ES2861449T3 (es) 2015-12-02 2021-10-06 Stcube & Co Inc Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018060833A1 (fr) 2016-09-27 2018-04-05 Novartis Ag Schéma posologique pour l'alpelisib, un inhibiteur de la phosphatidylinositol 3-kinase spécifique de l'isoforme alpha
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
MX2019005065A (es) 2016-11-03 2019-08-21 Kura Oncology Inc Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa.
US10954210B2 (en) 2016-12-08 2021-03-23 Hangzhou Solipharma Co., Ltd. Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof
KR20190140454A (ko) 2017-04-13 2019-12-19 아두로 바이오테크 홀딩스, 유럽 비.브이. 항-sirp 알파 항체
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
KR20200024158A (ko) 2017-05-31 2020-03-06 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
JP7256796B2 (ja) 2017-10-13 2023-04-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019113269A1 (fr) 2017-12-08 2019-06-13 Kura Oncology, Inc. Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
WO2019148412A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
CN112424149B (zh) 2018-05-18 2023-06-23 库拉肿瘤学公司 替吡法尼的合成
JP2021531007A (ja) 2018-07-20 2021-11-18 ピエール、ファーブル、メディカマン Ｖｉｓｔａに対する受容体
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020190604A1 (fr) 2019-03-15 2020-09-24 Kura Oncology, Inc. Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
CA3234276A1 (fr) * 2021-11-30 2023-06-08 Kura Oncology, Inc. Composes macrocycliques ayant une activite inhibitrice de la farnesyltransferase
WO2023141082A1 (fr) * 2022-01-20 2023-07-27 Teva Czech Industries S.R.O. Formes à l'état solide de tipifarnib et leur procédé de préparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101115A (en) * 1980-10-23 1983-01-12 Pfizer Ltd Thromboxane synthetase inhibitors
CA2002864C (fr) * 1988-11-29 1999-11-16 Eddy J. E. Freyne Derives de quinoline, quinazoline ou quinoxaline (1h-azol-1-ylmethyl) substitues
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren

Also Published As

Publication number Publication date
HU221227B1 (en) 2002-08-28
CY2289B1 (en) 2003-07-04
IL123568A0 (en) 1998-10-30
US6037350A (en) 2000-03-14
NO980927D0 (no) 1998-03-04
KR19990063891A (ko) 1999-07-26
NO314036B1 (no) 2003-01-20
SI1162201T1 (sl) 2006-08-31
DE69635966D1 (de) 2006-05-18
JP3257559B2 (ja) 2002-02-18
DK1162201T3 (da) 2006-07-17
ZA9610254B (en) 1998-06-05
IL123568A (en) 2001-08-08
TW494101B (en) 2002-07-11
WO1997021701A1 (fr) 1997-06-19
HK1012188A1 (en) 1999-07-30
TR199800825T2 (xx) 1998-08-21
KR100272676B1 (ko) 2000-11-15
MX9802068A (es) 1998-08-30
PT865440E (pt) 2002-09-30
PL184171B1 (pl) 2002-09-30
BR9610745A (pt) 1999-07-13
PL325962A1 (en) 1998-08-17
NO980927L (no) 1998-06-08
EA199800443A1 (ru) 1998-10-29
HUP9900185A3 (en) 1999-11-29
SK283335B6 (sk) 2003-06-03
AR004992A1 (es) 1999-04-07
EE9800146A (et) 1998-10-15
US6169096B1 (en) 2001-01-02
CN1203598A (zh) 1998-12-30
DE69620445T2 (de) 2002-12-12
UA57717C2 (uk) 2003-07-15
CA2231105C (fr) 2005-09-13
SK70498A3 (en) 1998-10-07
DE69620445D1 (de) 2002-05-08
EE03484B1 (et) 2001-08-15
JPH10511405A (ja) 1998-11-04
ATE215541T1 (de) 2002-04-15
MY114444A (en) 2002-10-31
SI0865440T1 (en) 2002-08-31
PT1162201E (pt) 2006-08-31
NZ320244A (en) 1999-06-29
HUP9900185A2 (hu) 1999-04-28
HRP960576A2 (en) 1998-02-28
BG102458A (en) 1999-06-30
EP1162201A2 (fr) 2001-12-12
CZ293296B6 (cs) 2004-03-17
CA2231105A1 (fr) 1997-06-19
AP1108A (en) 2002-10-02
ES2260156T3 (es) 2006-11-01
AU7294896A (en) 1997-07-03
EP0865440A1 (fr) 1998-09-23
ES2175137T3 (es) 2002-11-16
DK0865440T3 (da) 2002-07-22
DE69635966T2 (de) 2006-11-30
CZ157398A3 (cs) 1998-10-14
EP1162201B1 (fr) 2006-03-29
US6420387B1 (en) 2002-07-16
HK1042482A1 (en) 2002-08-16
AU711142B2 (en) 1999-10-07
EP1162201A3 (fr) 2003-11-26
EA000710B1 (ru) 2000-02-28
HK1042482B (zh) 2006-06-09
EP0865440B1 (fr) 2002-04-03
BG62615B1 (en) 2000-03-31
CN1101392C (zh) 2003-02-12
EP1162201A9 (fr) 2002-04-03
AP9801257A0 (en) 1998-06-30
ATE321757T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
NZ320244A (en) Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
IL123155A0 (en) 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
GR3031409T3 (en) 4,9-ethano-benzo(f)isoindole derivatives as farnesyl transferase inhibitors
HUP9802424A3 (en) Farnesyl transferase inhibiting 2-quinolone derivatives
ZA985778B (en) Inhibitors of farnesyl protein transferase.
EE9700314A (et) Farnesüül-proteiini transferaasi inhibiitorid
EP0696593A3 (fr) Inhibiteurs de la farnesyl protéine transférase
EP0664789A4 (en) Inhibitors of farnesyl protein transferase.
IL124197A (en) Inhibitors of farnesyl protein transferase
IL126833A0 (en) Inhibitors of protein farnesyl transferase
EP0918771A4 (fr) Thiadioxobenzodiazepines utilises comme inhibiteurs de la farnesyle proteine transferase
EP1027042A4 (fr) Inhibiteurs de la transferase farnesyle proteine
IL130453A0 (en) Farnesyl transferase inhibitors
AU4329397A (en) Semipeptoid farnesyl protein transferase inhibitors and analogs thereof
HUP9903221A3 (en) Inhibitors of protein farnesyl transferase
IL141626A0 (en) Farnesyl transferase inhibitors
ZA971621B (en) Inhibitors of farnesyl protein transferase
IL155594A0 (en) Farnesyl transferase inhibitors

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20151110

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20161205